the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim
Company profile
Ticker
FDMT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
4D Molecular Therapeutics Inc, 4D Molecular Therapeutics Inc.
SEC CIK
Corporate docs
IRS number
473506994
FDMT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29 Feb 24
8-K
Other Events
9 Feb 24
424B5
Prospectus supplement for primary offering
8 Feb 24
FWP
Free writing prospectus
7 Feb 24
424B5
Prospectus supplement for primary offering
5 Feb 24
Latest ownership filings
4
Scott Bizily
18 Apr 24
4
Scott Bizily
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Scott Bizily
29 Mar 24
4
Scott Bizily
20 Mar 24
4
Scott Bizily
29 Feb 24
4
Scott Bizily
21 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Kirn David
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 275.68 mm | 275.68 mm | 275.68 mm | 275.68 mm | 275.68 mm | 275.68 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.66 mm | 8.74 mm | 390.33 k | 6.11 mm |
Cash used (since last report) | n/a | n/a | 30.98 mm | 58.15 mm | 2.60 mm | 40.65 mm |
Cash remaining | n/a | n/a | 244.70 mm | 217.53 mm | 273.08 mm | 235.03 mm |
Runway (months of cash) | n/a | n/a | 52.5 | 24.9 | 699.6 | 38.4 |
Institutional ownership, Q2 2023
95.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 104 |
Opened positions | 24 |
Closed positions | 15 |
Increased positions | 48 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 746.48 bn |
Total shares | 48.71 mm |
Total puts | 101.00 k |
Total calls | 60.50 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Viking Global Investors | 4.79 mm | $86.52 bn |
Biotechnology Value Fund L P | 4.01 mm | $22.76 mm |
BVF | 4.01 mm | $72.41 bn |
Ra Capital Management | 3.07 mm | $55.47 bn |
VR Adviser | 3.00 mm | $54.21 bn |
BLK Blackrock | 2.91 mm | $52.66 bn |
Venrock Healthcare Capital Partners III | 2.89 mm | $48.92 mm |
JHG Janus Henderson | 2.84 mm | $51.28 bn |
Deep Track Capital | 2.78 mm | $50.20 bn |
STT State Street | 2.05 mm | $37.05 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Scott Bizily | Common Stock | Sell | Dispose S | No | Yes | 25.74 | 1,750 | 45.05 k | 1,737 |
16 Apr 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 8.04 | 1,250 | 10.05 k | 3,487 |
16 Apr 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 6.49 | 500 | 3.25 k | 2,237 |
16 Apr 24 | Scott Bizily | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 8.04 | 1,250 | 10.05 k | 39,168 |
16 Apr 24 | Scott Bizily | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 6.49 | 500 | 3.25 k | 14,211 |
1 Apr 24 | Scott Bizily | Common Stock | Sell | Dispose S | No | Yes | 31.78 | 8,153 | 259.10 k | 1,737 |
1 Apr 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 20.24 | 1,909 | 38.64 k | 9,890 |
1 Apr 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 15.78 | 1,996 | 31.50 k | 7,981 |
1 Apr 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 8.04 | 2,916 | 23.44 k | 5,985 |
1 Apr 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 6.49 | 1,332 | 8.64 k | 3,069 |
News
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
18 Apr 24
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40
15 Apr 24
Barclays Initiates Coverage On 4D Molecular Therapeutics with Overweight Rating, Announces Price Target of $45
15 Apr 24
BMO Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $63
1 Apr 24
Jefferies Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $58
1 Apr 24
Press releases
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
12 Feb 24
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
6 Feb 24
Thinking about trading options or stock in C3.ai, Meta Platforms, 4D Molecular Therapeutics, Li Auto, or Varonis Systems?
6 Feb 24
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
5 Feb 24
Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?
5 Feb 24